WEKO3
アイテム
{"_buckets": {"deposit": "6e37246c-7e68-4baa-bfb1-d34ff21d4360"}, "_deposit": {"created_by": 1, "id": "3141", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "3141"}, "status": "published"}, "_oai": {"id": "oai:yamanashi.repo.nii.ac.jp:00003141", "sets": ["293"]}, "author_link": ["14639", "14637", "14635", "14636", "14640", "14638"], "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "1992", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "95", "bibliographicPageStart": "89", "bibliographicVolumeNumber": "7", "bibliographic_titles": [{"bibliographic_title": "山梨医科大学雑誌"}, {"bibliographic_title": "山梨医科大学雑誌", "bibliographic_titleLang": "en"}]}]}, "item_10001_creator_2": {"attribute_name": "著者名", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "NAKAGOMI, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "14635", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "IWASAKI, Masaru"}], "nameIdentifiers": [{"nameIdentifier": "14636", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "TAKANO, Kunio"}], "nameIdentifiers": [{"nameIdentifier": "14637", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "MATSUKAWA, Tetsunosuke"}], "nameIdentifiers": [{"nameIdentifier": "14638", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "UENO, Akira"}], "nameIdentifiers": [{"nameIdentifier": "14639", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "UMEKITA, Nobutaka"}], "nameIdentifiers": [{"nameIdentifier": "14640", "nameIdentifierScheme": "WEKO"}]}]}, "item_10001_description_5": {"attribute_name": "内容", "attribute_value_mlt": [{"subitem_description": "Since 1986, we have been investigating repetitive intraportal administration of anticancer agents as prophylaxis for liver metastasis after gastrointestinal cancer surgery. Intraportal mitomycin C (MMC: 4 mg) was given on the day of operation and on postoperative days 1-6. A preliminary pharmacokinetic study of intraportal MMC administration was performed in a rabbit model. A high first-pass extraction ratio was found at doses of 0.05 and 0.1 mg/kg, and it decreased at the higher doses of 0.2 and 0.4 mg/kg. The clinical dose of 4 mg corresponded to 0.05-0.1 mg/kg in the rabbit model and was considered to be within the optimal dose range. The side effects and clinical outcome for patients treated with intraportal MMC were compared with those for a control group. The controls included an MMC (+) group that received intravenous MMC, and a MMC (-) group that did not. The intraportal MMC group showed less toxicity compared with the MMC (+) group and a prospective effect on survival and liver metatstasls. These results suggested that our schedule for repetitive intraportal MMC was adequate.", "subitem_description_type": "Other"}]}, "item_10001_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.34429/00003134", "subitem_identifier_reg_type": "JaLC"}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "山梨医科大学医学会"}]}, "item_10001_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AN10044054", "subitem_source_identifier_type": "NCID"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0912-0025", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-02-27"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "AN10044054_07_03_02.pdf", "filesize": [{"value": "625.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 625200.0, "url": {"label": "AN10044054_07_03_02.pdf", "url": "https://yamanashi.repo.nii.ac.jp/record/3141/files/AN10044054_07_03_02.pdf"}, "version_id": "a997f163-1807-408a-a91c-9ed5a33a4e03"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Repetitive portal administration", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Mitomycin C", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Pharmacokinetic study", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "\u003cOriginal Article\u003e Clinical Trial of Repetitive Portal Administration of Anticancer Drug as a Prophylactic Modality for Liver Metastasis - A Pilot Study of the Optimal Dosage and Reduced Toxicity -", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "\u003cOriginal Article\u003e Clinical Trial of Repetitive Portal Administration of Anticancer Drug as a Prophylactic Modality for Liver Metastasis - A Pilot Study of the Optimal Dosage and Reduced Toxicity -"}]}, "item_type_id": "10001", "owner": "1", "path": ["293"], "permalink_uri": "https://doi.org/10.34429/00003134", "pubdate": {"attribute_name": "公開日", "attribute_value": "2010-05-18"}, "publish_date": "2010-05-18", "publish_status": "0", "recid": "3141", "relation": {}, "relation_version_is_last": true, "title": ["\u003cOriginal Article\u003e Clinical Trial of Repetitive Portal Administration of Anticancer Drug as a Prophylactic Modality for Liver Metastasis - A Pilot Study of the Optimal Dosage and Reduced Toxicity -"], "weko_shared_id": -1}
<Original Article> Clinical Trial of Repetitive Portal Administration of Anticancer Drug as a Prophylactic Modality for Liver Metastasis - A Pilot Study of the Optimal Dosage and Reduced Toxicity -
https://doi.org/10.34429/00003134
https://doi.org/10.34429/00003134fd094570-398a-4e56-a929-2a76c8a6c07c
名前 / ファイル | ライセンス | アクション |
---|---|---|
AN10044054_07_03_02.pdf (625.2 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2010-05-18 | |||||
タイトル | ||||||
タイトル | <Original Article> Clinical Trial of Repetitive Portal Administration of Anticancer Drug as a Prophylactic Modality for Liver Metastasis - A Pilot Study of the Optimal Dosage and Reduced Toxicity - | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題 | Repetitive portal administration | |||||
キーワード | ||||||
主題 | Mitomycin C | |||||
キーワード | ||||||
主題 | Pharmacokinetic study | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
ID登録 | ||||||
ID登録 | 10.34429/00003134 | |||||
ID登録タイプ | JaLC | |||||
著者名 |
NAKAGOMI, Hiroshi
× NAKAGOMI, Hiroshi× IWASAKI, Masaru× TAKANO, Kunio× MATSUKAWA, Tetsunosuke× UENO, Akira× UMEKITA, Nobutaka |
|||||
内容 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Since 1986, we have been investigating repetitive intraportal administration of anticancer agents as prophylaxis for liver metastasis after gastrointestinal cancer surgery. Intraportal mitomycin C (MMC: 4 mg) was given on the day of operation and on postoperative days 1-6. A preliminary pharmacokinetic study of intraportal MMC administration was performed in a rabbit model. A high first-pass extraction ratio was found at doses of 0.05 and 0.1 mg/kg, and it decreased at the higher doses of 0.2 and 0.4 mg/kg. The clinical dose of 4 mg corresponded to 0.05-0.1 mg/kg in the rabbit model and was considered to be within the optimal dose range. The side effects and clinical outcome for patients treated with intraportal MMC were compared with those for a control group. The controls included an MMC (+) group that received intravenous MMC, and a MMC (-) group that did not. The intraportal MMC group showed less toxicity compared with the MMC (+) group and a prospective effect on survival and liver metatstasls. These results suggested that our schedule for repetitive intraportal MMC was adequate. | |||||
出版者 | ||||||
出版者 | 山梨医科大学医学会 | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0912-0025 | |||||
NCID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN10044054 | |||||
書誌情報 |
山梨医科大学雑誌 en : 山梨医科大学雑誌 巻 7, 号 3, p. 89-95, 発行日 1992 |
|||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 |